Inventor · disambiguated record
Yaron R. Hadari
Also filed as: HADARI YARON · HADARI YARON R
25 granted patents·11 pending applications·104 citations·filing 2002–2025
95Inventor score
Files withSHY Therapeutics LLC20CELLDEX THERAPEUTICS INC10KOLLTAN PHARMACEUTICALS INC3YEDA RES & DEV2HADARI YARON1
Top patents by PatentIndex Score
36 records- 0195US10781267B2Methods of treating by administering anti-kit antibodiesCELLDEX THERAPEUTICS INC·Filed 2018·Granted Sep 22, 2020·7 cites·22 claims
- 0293US12168668B2Compounds for the treatment of cancer and inflammatory diseaseSHY Therapeutics LLC·Filed 2022·Granted Dec 17, 2024·1 cites·16 claims
- 0392US10870657B2Compounds for the treatment of cancer and inflammatory diseaseSHY Therapeutics LLC·Filed 2019·Granted Dec 22, 2020·4 cites·7 claims
- 0492US10184007B2Methods of treating a kit-associated cancer by administering anti-kit antibodiesCELLDEX THERAPEUTICS INC·Filed 2017·Granted Jan 22, 2019·9 cites·20 claims
- 0592US9605081B2Polynucleotides encoding anti-kit antibodiesKOLLTAN PHARMACEUTICALS INC·Filed 2016·Granted Mar 28, 2017·13 cites·8 claims
- 0690US11026930B1Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic diseaseSHY Therapeutics LLC·Filed 2020·Granted Jun 8, 2021·2 cites·16 claims
- 0790US9540443B2Anti-kit antibodiesHADARI YARON·Filed 2012·Granted Jan 10, 2017·21 cites·41 claims
- 0890US9334332B2Anti-kit antibodiesKOLLTAN PHARMACEUTICALS INC·Filed 2013·Granted May 10, 2016·14 cites·58 claims
- 0989US10793639B2Methods of treating by administering anti-kit antibodiesCELLDEX THERAPEUTICS INC·Filed 2018·Granted Oct 6, 2020·3 cites·22 claims
- 1089US10189907B2Polynucleotides encoding anti-KIT antibodiesCELLDEX THERAPEUTICS INC·Filed 2016·Granted Jan 29, 2019·6 cites·34 claims
- 1188US10588894B2Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic diseaseSHY Therapeutics LLC·Filed 2018·Granted Mar 17, 2020·4 cites·6 claims
- 1288US10221191B2Compounds for the treatment of cancer and inflammatory diseaseSHY Therapeutics LLC·Filed 2016·Granted Mar 5, 2019·5 cites·5 claims
- 1387US2024150493A1Anti-kit antibodies and uses thereofCELLDEX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1487US2025122216A1Compounds for the Treatment of Cancer and Inflammatory DiseaseSHY Therapeutics LLC·Filed 2024·Application pending·0 cites
- 1586US11891452B2Anti-kit antibodies and uses thereofCELLDEX THERAPEUTICS INC·Filed 2020·Granted Feb 6, 2024·1 cites·20 claims
- 1686US10940139B2Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic diseaseSHY Therapeutics LLC·Filed 2019·Granted Mar 9, 2021·3 cites·27 claims
- 1785US11000515B2Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic diseaseSHY Therapeutics LLC·Filed 2019·Granted May 11, 2021·2 cites·58 claims
- 1885US2024141063A1Anti-kit antibodies and uses thereofCELLDEX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1984US10933054B2Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic diseaseSHY Therapeutics LLC·Filed 2019·Granted Mar 2, 2021·2 cites·30 claims
- 2081US2023149369A1Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic DiseaseSHY Therapeutics LLC·Filed 2022·Application pending·0 cites
- 2178US12391705B2Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic diseaseSHY Therapeutics LLC·Filed 2019·Granted Aug 19, 2025·1 cites·27 claims
- 2278US11541041B1Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic diseaseSHY Therapeutics LLC·Filed 2021·Granted Jan 3, 2023·0 cites·39 claims
- 2376US11213515B1Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic diseaseSHY Therapeutics LLC·Filed 2021·Granted Jan 4, 2022·0 cites·33 claims
- 2474US7176181B2Compositions and methods of using galectin-8 as an inhibitor of tumor cell growthYEDA RES & DEV·Filed 2002·Granted Feb 13, 2007·6 cites·5 claims
- 2573US11884699B2Anti-KIT antibodies and uses thereofCELLDEX THERAPEUTICS INC·Filed 2020·Granted Jan 30, 2024·0 cites·20 claims
- 2673US11560390B2Compounds for the treatment of cancer and inflammatory diseaseSHY Therapeutics LLC·Filed 2020·Granted Jan 24, 2023·0 cites·5 claims
- 2771US12459951B2Compounds that interact with RAS superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic diseaseSHY Therapeutics LLC·Filed 2024·Granted Nov 4, 2025·0 cites·46 claims
- 2869US2025296938A1Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic DiseaseSHY Therapeutics LLC·Filed 2025·Application pending·0 cites
- 2964US2025289825A1Compounds that interact with ras superfamily proteins for treatment of cancers, inflammatory diseases, rasopathies, and fibrotic diseaseSHY Therapeutics LLC·Filed 2025·Application pending·0 cites
- 3062US11884734B2Anti-MET antibodies and methods of use thereofCELLDEX THERAPEUTICS INC·Filed 2020·Granted Jan 30, 2024·0 cites·16 claims
- 3157US2024309015A1Methods for the Treatment of Fibrotic DiseaseSHY Therapeutics LLC·Filed 2022·Application pending·0 cites
- 3257US2024124483A1Methods for the Treatment of Fibrotic DiseaseSHY Therapeutics LLC·Filed 2022·Application pending·0 cites
- 3355US2023227466A1Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic diseaseSHY Therapeutics LLC·Filed 2021·Application pending·0 cites
- 3454US7416725B2Compositions and methods of using galectin-8 as an inhibitor of tumor cell growthYEDA RES & DEV·Filed 2006·Granted Aug 26, 2008·0 cites·1 claims
- 3548US2018057595A1Anti-MET Antibodies and Methods of Use ThereofCELLDEX THERAPEUTICS INC·Filed 2016·Application pending·0 cites
- 3637US2013011406A1Anti-kit antibodies and uses thereofKOLLTAN PHARMACEUTICALS INC·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yaron R. Hadari files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →